Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
about
Natural Killer Cells for Therapy of LeukemiaNatural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK CellsNatural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivitySelection and expansion of natural killer cells for NK cell-based immunotherapyStrategies for combining immunotherapy with radiation for anticancer therapyNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyNatural killer cell biology: an update and future directionsAdvantages and clinical applications of natural killer cells in cancer immunotherapyIn vivo monitoring of natural killer cell trafficking during tumor immunotherapySelective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptorHigh log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapyNatural killer cells in human cancer: from biological functions to clinical applicationsManufacturing Natural Killer Cells as Medicinal ProductsUnderstanding of molecular mechanisms in natural killer cell therapyPhase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancerFocused ultrasound delivers targeted immune cells to metastatic brain tumorsChimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor ImmunityNK cell-based immunotherapy for malignant diseases.Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveOpportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseGMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapyAdoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigensAutologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusionsLarge-scale ex vivo expansion and characterization of natural killer cells for clinical applications.Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.(19)F-MRI for monitoring human NK cells in vivoEx vivo generation of highly purified and activated natural killer cells from human peripheral blood.A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.New frontiers in cell-based immunotherapy of cancer.An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.
P2860
Q26745906-BD5AF488-70D8-49B5-A471-68B9B4A8BCD8Q26751020-36ADC1B7-0C76-4342-B1A1-A4EE8B87EEB2Q26771449-16CB20CE-1A91-466D-9D16-AA38C51A7E6AQ26773135-8E14FF2E-0778-49D1-BC1D-E7A12DBF2020Q26774777-6326C60B-AC8F-42C6-88F3-C567F735C091Q26796675-C6E1B719-5C4E-48CE-BBAF-41F4E3200554Q26797345-200DA78E-07D9-4E99-8064-8682934E7D26Q26830512-671008EE-6697-460A-B89A-F33E8AFDF675Q26999224-EF6B7BDA-CD1D-4875-8C39-B2EBFA69CAD6Q27011245-FEC36C04-591D-4138-8AB1-302771BBB6B7Q27318470-75FD0583-C55D-44DD-9F86-39DAD421DC34Q27334458-1613C1E7-FC21-4E6C-93CC-D1F368258779Q27691427-295199D8-282C-4912-B58F-BA203E6F94D6Q28069992-4703F682-670F-430C-AC55-82BC3C4972A4Q28086976-2F599906-E1A8-47E5-8D97-CAD7A0ACF714Q28266580-99CF3695-5BCE-4599-93CC-67802C576E3AQ30441716-08DE78AF-D089-4282-B2F5-EF8FD72831A7Q33700795-E8DC6441-0AC7-4633-83B7-38E83F0653B3Q33827433-EE6882AA-B2C6-4A2D-BDB4-354199934742Q34042430-893A5FBA-3741-42F4-91B6-0EC1F6169C8CQ34180695-E0A8BFAB-00BD-4DDB-AAFC-7A9FD780DC95Q34307792-A75BF820-B03F-4F8E-BEC3-9DB9AA142868Q34551581-7D8FF3C4-DCCF-410B-BA02-8AA92E2C10E7Q34712771-203C4CCE-963C-4671-889F-6398EE654EB2Q35269067-22245D44-BD63-48FD-84FD-D73F9CD94E7AQ35834087-F7F0F9D8-F643-4680-9FD7-74D7BA05469BQ36055257-D805C759-4116-4E0F-9670-6B989743031CQ36094697-3D7CB20E-DA69-42E1-A2B2-B2997DDD0166Q36114222-735DE8A8-424E-4862-B099-F0CE7C30E8A0Q36245682-AE8D1D58-B7A8-4153-BD79-87D594CDEE51Q36377047-7B61C931-1843-4CFF-BD7D-EF8D18C30A76Q36546883-9475F849-5AD2-43E0-85FA-1FB327EB29D7Q36676064-3D1857B7-BC3F-476E-A43F-D49552C683A4Q36821054-CFA22F3C-183B-4C44-ACDC-A2B8CD5F33C3Q37012655-80C0471B-B166-4A8E-9034-90CA152DF363Q37122377-B7FC16B2-1CA4-4861-B42F-5CC578F9608EQ37141237-9E401223-C8B3-45C3-8028-5B127670C517Q37434670-0CB166DE-5F26-4059-920D-5423AF3DB229Q37481361-304C0915-447F-45D5-A2DB-444E1E5FEB1FQ37488222-CA88E613-B92D-416E-8472-3FC590910138
P2860
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@en
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@nl
type
label
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@en
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@nl
prefLabel
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@en
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@nl
P2093
P1433
P1476
Infusion of the allogeneic cel ...... or melanoma: a phase I trial.
@en
P2093
H Klingemann
J Martinson
M Swearingen
P304
P356
10.1080/14653240802301872
P577
2008-01-01T00:00:00Z